The study examined the effectiveness of treatment with camrelizumab (an immune-boosting drug) in combination with standard chemoradiotherapy in patients with high-risk nasopharyngeal cancer. In a multicenter randomized phase 3 study, 390 patients from seven Chinese hospitals were enrolled, who were divided into two groups - one receiving camrelizumab together with chemoradiotherapy and the other only standard treatment. At a median follow-up of 39.9 months, progression-free survival was higher in the camrelizumab group (83.4% versus 75.2% at 36 months). Adverse effects were similar in both groups – acute adverse events occurred in 50.5% of patients with camrelizumab and 48.7% without it. Immunological adverse effects occurred in 10.2% of patients in the camrelizumab group. The results show that the addition of camrelizumab to standard treatment improved progression-free survival in patients with high-risk nasopharyngeal carcinoma after induction chemotherapy.